• Issue

    Alimentary Pharmacology & Therapeutics: Volume 52, Issue 10

    1537-1624
    November 2020
Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 1537-1539
  • First Published: 21 October 2020

REVIEW ARTICLE

East Asia expert opinion on treatment initiation for chronic hepatitis B

Jia-Horng Kao,  Tsung-Hui Hu,  Jidong Jia,  Masayuki Kurosaki,  Young-Suk Lim,  Han-Chieh Lin,  Dong Hyun Sinn,  Yasuhito Tanaka,  Vincent Wai-Sun Wong,  Man-Fung Yuen, 
  • Pages: 1540-1550
  • First Published: 20 September 2020

BIOLOGIC AGENTS FOR IBD DURING PREGNANCY

Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure

Emma Flanagan,  Peter R. Gibson,  Emily K. Wright,  Gregory T. Moore,  Miles P. Sparrow,  William Connell,  Michael A. Kamm,  Jakob Begun,  Britt Christensen,  Peter De Cruz,  Edward Shelton,  Damian Dowling,  Jane M. Andrews,  Steven J. Brown,  Olga Niewiadomski,  Mark G. Ward,  Ourania Rosella,  Gennaro Rosella,  Katerina V. Kiburg,  Alyson L. Ross,  Sally J. Bell,  The PICCOLO Study Group , 
  • Pages: 1551-1562
  • First Published: 27 September 2020

MRE FINDINGS AND TREATMENT RESPONSE IN CROHN'S DISEASE

Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease

Jordi Rimola,  Agnès Fernàndez-Clotet,  Nunzia Capozzi,  Sònia Rojas-Farreras,  Ignacio Alfaro,  Sonia Rodríguez,  Maria-Carme Masamunt,  Elena Ricart,  Ingrid Ordás,  Julian Panés, 
  • Pages: 1563-1573
  • First Published: 04 September 2020

BIOPSY SAMPLING IN UC

Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study

Robert Battat,  Niels Vande Casteele,  Rish K. Pai,  Zhongya Wang,  Guangyong Zou,  John W. D. McDonald,  Marjolijn Duijvestein,  Jenny Jeyarajah,  Claire E. Parker,  Tanja Van Viegen,  Sigrid A. Nelson,  Brigid S. Boland,  Siddharth Singh,  Parambir S. Dulai,  Mark A. Valasek,  Brian G. Feagan,  Vipul Jairath,  William J. Sandborn, 
  • Pages: 1574-1582
  • First Published: 27 September 2020

HEPATITIS C INFECTION

Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes

Slim Fourati,  Christophe Rodriguez,  Alexandre Soulier,  Flora Donati,  Sabah Hamadat,  Lila Poiteau,  Vanessa Demontant,  Rozenn Brillet,  Nazim Ahnou,  Guillaume Gricourt,  Stéphane Chevaliez,  Abdelhakim Ahmed-Belkacem,  Jean-Michel Pawlotsky, 
  • Pages: 1583-1591
  • First Published: 04 September 2020

Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US

Wei Wang,  Vincent Lo Re III,  Yi Guo,  Hong Xiao,  Joshua Brown,  Haesuk Park, 
  • Pages: 1592-1602
  • First Published: 15 September 2020

NAFLD

Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease

Youngae Jung,  Min Kyung Lee,  Puneet Puri,  Bo Kyung Koo,  Sae Kyung Joo,  Seo Young Jang,  Dong Hyeon Lee,  Yong Jin Jung,  Byeong Gwan Kim,  Kook Lae Lee,  Tae-Sik Park,  Ki-Tae Kang,  Do Hyun Ryu,  Sang Won Kang,  Donghee Kim,  Sohee Oh,  Won Kim,  Geum-Sook Hwang, 
  • Pages: 1603-1614
  • First Published: 06 September 2020

INVITED EDITORIALS

Free Access

Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?

Christopher Ma,  Siddharth Singh,  Joan Heatherington,  Remo Panaccione, 
  • Pages: 1615-1616
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Asscher et al papers. To view these articles, visit https://doi.org/10.1111/apt.16073 and https://doi.org/10.1111/apt.16106

Free Access

Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply

Vera E. R. Asscher,  Vince B. C. Biemans,  Frank Hoentjen,  P. W. Jeroen Maljaars, on behalf of the Dutch Initiative on Crohn and Colitis (ICC) , 
  • Pages: 1617-1618
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Asscher et al and Ma et al papers. To view these articles, visit https://doi.org/10.1111/apt.16073 and https://doi.org/10.1111/apt.16098

LETTERS TO THE EDITORS

Free Access

Letter: rationalising aminosalicylates in inflammatory bowel disease

Steven Nicolaides,  Abhinav Vasudevan,  Daniel van Langenberg, 
  • Pages: 1619-1620
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Chapman et al papers. To view these articles, visit https://doi.org/10.1111/apt.15771 and https://doi.org/10.1111/apt.16113

Free Access

Letter: rationalising aminosalicylates in inflammatory bowel disease—authors' reply

Thomas P. Chapman,  Catarina Frias Gomes,  Edouard Louis,  Jean-Frédéric Colombel,  Jack Satsangi, 
  • Page: 1621
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Chapman et al and Nicolaides et al papers. To view these articles, visit https://doi.org/10.1111/apt.15771 and https://doi.org/10.1111/apt.16107

Free Access

Letter: intestinal microbiota transfer—updating the nomenclature to increase acceptability

Laura J. Craven,  James R. McIlroy,  Benjamin H. Mullish,  Julian R. Marchesi, 
  • Pages: 1622-1623
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Lai et al paper. To view this article, visit https://doi.org/10.1111/apt.15116

Free Access

Letter: substantial under-diagnosis of NAFLD – more efforts are needed globally

Saad Emhmed Ali,  Mindie H. Nguyen, 
  • Page: 1624
  • First Published: 21 October 2020

LINKED CONTENT

This article is linked to Canbay et al paper. To view this article, visit https://doi.org/10.1111/apt.16016